ATE190728T1 - Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper - Google Patents

Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper

Info

Publication number
ATE190728T1
ATE190728T1 AT96926554T AT96926554T ATE190728T1 AT E190728 T1 ATE190728 T1 AT E190728T1 AT 96926554 T AT96926554 T AT 96926554T AT 96926554 T AT96926554 T AT 96926554T AT E190728 T1 ATE190728 T1 AT E190728T1
Authority
AT
Austria
Prior art keywords
quantitative determination
serum amyloid
acute phase
proteins
saa
Prior art date
Application number
AT96926554T
Other languages
English (en)
Inventor
John Martin Doyle
Hazel Audrey Hobson
Alexander Steven Whitehead
Original Assignee
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity College Dublin filed Critical Trinity College Dublin
Application granted granted Critical
Publication of ATE190728T1 publication Critical patent/ATE190728T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96926554T 1995-07-21 1996-07-19 Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper ATE190728T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE950553 1995-07-21
PCT/IE1996/000042 WO1997004317A1 (en) 1995-07-21 1996-07-19 Method for the quantitative measurement of human acute phase serum amyloid a protein; recombinant protein; specific antibody

Publications (1)

Publication Number Publication Date
ATE190728T1 true ATE190728T1 (de) 2000-04-15

Family

ID=11040829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926554T ATE190728T1 (de) 1995-07-21 1996-07-19 Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper

Country Status (9)

Country Link
US (1) US6194163B1 (de)
EP (1) EP0842434B1 (de)
JP (1) JPH11510596A (de)
AT (1) ATE190728T1 (de)
AU (1) AU711163B2 (de)
BR (1) BR9609771A (de)
CA (1) CA2227537A1 (de)
DE (1) DE69607176T2 (de)
WO (1) WO1997004317A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6321164B1 (en) 1995-06-07 2001-11-20 Akzo Nobel N.V. Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
US6429017B1 (en) 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US6898532B1 (en) 1995-06-07 2005-05-24 Biomerieux, Inc. Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US6502040B2 (en) 1997-12-31 2002-12-31 Biomerieux, Inc. Method for presenting thrombosis and hemostasis assay data
ES2231167T3 (es) 1999-02-04 2005-05-16 Biomerieux, Inc. Procedimiento y aparato para predecir la disfuncion hemostatica en una muestra de un paciente.
US6251624B1 (en) 1999-03-12 2001-06-26 Akzo Nobel N.V. Apparatus and method for detecting, quantifying and characterizing microorganisms
DE69933707T2 (de) 1999-08-25 2007-08-23 Accuplex, L.L.C. Serum amyloid a als marker für entzündungsreaktion, milchqualität und die anwesenheit von kolostrum in milch
CA2387907A1 (en) 1999-10-22 2001-05-03 The Board Of Regents Of The University Of Nebraska Serum amyloid a isoform from colostrum
US7179612B2 (en) 2000-06-09 2007-02-20 Biomerieux, Inc. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
CA2438137A1 (en) * 2001-02-13 2002-08-22 Universiteit Gent Device and method for detecting the presence of an analyte
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US20020160533A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons
US20040072181A1 (en) 2002-01-22 2004-04-15 Whitehead Alexander Steven Methods for determining drug responsiveness
US20040203031A1 (en) 2002-04-03 2004-10-14 University Of Pennsylvania Methods for determining drug responsiveness
US7368546B2 (en) 2003-01-21 2008-05-06 The Board Of Regents Of The University Of Nebraska Human SAA3 nucleic acid molecule, protein, and methods of use for same
US20090280108A1 (en) * 2004-12-10 2009-11-12 Da-Wei Gong Serum amyloid a protein in inflammation and obesity
EP1943359B1 (de) * 2005-09-30 2011-06-29 Centocor Ortho Biotech Inc. Zusammensetzungen und verfahren für il13-biomarker
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
US10288537B2 (en) * 2013-02-04 2019-05-14 Epona Biotech Ltd Test fluid collection system
CN106053862B (zh) * 2016-05-16 2017-09-15 河北艾驰生物科技有限公司 血清淀粉样蛋白a（saa）测定试剂盒
CN106198961A (zh) * 2016-07-21 2016-12-07 上海奥普生物医药有限公司 一种定量检测血清淀粉样蛋白a的乳胶增强免疫比浊试剂盒及其制备方法
CN108680751A (zh) * 2018-04-04 2018-10-19 苏州遵道生物科技有限公司 定量检测血清淀粉样蛋白a的时间分辨荧光免疫层析试纸条及其制备方法
CN113189335A (zh) * 2021-06-17 2021-07-30 上海中乔新舟生物科技有限公司 血清淀粉样蛋白a2在制备检测肺癌试剂盒中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
JPS6344895A (ja) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドａ蛋白質単クロ−ン性抗体
US5126240A (en) * 1986-09-29 1992-06-30 Curtiss Linda K Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i
US5262303A (en) * 1989-10-13 1993-11-16 Trustees Of Boston University Ligand/anti-ligand assays for adherent proteins
US5290686A (en) * 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
JPH08178921A (ja) * 1994-12-21 1996-07-12 Cosmo Sogo Kenkyusho:Kk 血清アミロイドａの免疫学的測定方法

Also Published As

Publication number Publication date
WO1997004317A1 (en) 1997-02-06
US6194163B1 (en) 2001-02-27
JPH11510596A (ja) 1999-09-14
BR9609771A (pt) 1999-12-21
DE69607176D1 (de) 2000-04-20
EP0842434A1 (de) 1998-05-20
AU711163B2 (en) 1999-10-07
AU6667096A (en) 1997-02-18
DE69607176T2 (de) 2000-09-21
CA2227537A1 (en) 1997-02-06
EP0842434B1 (de) 2000-03-15

Similar Documents

Publication Publication Date Title
ATE190728T1 (de) Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper
US5817470A (en) Immobilization of antigens to solid support by the mussel adhesive polyphenolic protein and the method for use therein
ATE226729T1 (de) Quantitative immunochromatographische assays
KR930022086A (ko) 아밀로이드 전구체 단백질의 단백질가수분해에 근거한 알츠하이머병(Alzheimer's disease)의 진단분석
US20070059682A1 (en) Method to increase specificity and/or accuracy of lateral flow immunoassays
RU2213973C2 (ru) СПОСОБ ОПРЕДЕЛЕНИЯ АНТИБИОТИКОВ, СОДЕРЖАЩИХ β-ЛАКТАМНЫЙ ЦИКЛ, В ЖИДКОСТИ БИОЛОГИЧЕСКОГО ПРОИСХОЖДЕНИЯ И АНАЛИТИЧЕСКИЙ НАБОР ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ
WO2001025788A1 (en) Non-separation heterogenous assay for biological substances
ES512498A0 (es) "metodo y su correspondiente aparato para el ensayo de anticuerpos con respecto a antigenos solubles".
KR100394940B1 (ko) 간 질환 진단을 위한 혈중 아사이알로당단백질양의측정방법 및 측정용 킷트
CA2393127A1 (en) Diagnostic assay for stroke
Gardies et al. Feasibility of an immunosensor based upon capacitance measurements
US4729961A (en) Process for the detection and assay by erythroadsorption
Phillips Determination of in situ tissue neuropeptides by capillary immunoelectrophoresis
US7067264B2 (en) Test device for detecting human blood and method of use
EP0643835A4 (de) Htlv-i/htlv-ii assay und verfahren.
AU683072B2 (en) Test device
EP1166113A1 (de) Lipopoysaccharid-immunoassay und testvorrichtung
EP1898215A1 (de) Verfahren zum testen endokriner substanz in proben
KR20160120675A (ko) 래피드 정량 진단 키트
CA2213083A1 (en) Detection of antibody production
US6168921B1 (en) Method for the quantitative and/or qualitative determination of atoms or molecules
JPH09210955A (ja) タンパク質センサ
WO2001027621A3 (en) Competitive inhibition elisa for antibody detection
US20050118728A1 (en) Two-layer antibody capture system
RU2741382C1 (ru) Способ иммуноферментного анализа идиотипических и антиидиотипических антител к бензо[а]пирену в биологических жидкостях человека

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties